Skip Navigation


JAC Advance Access originally published online on August 22, 2007
Journal of Antimicrobial Chemotherapy 2007 60(4):843-848; doi:10.1093/jac/dkm274
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
60/4/843    most recent
dkm274v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sagir, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sagir, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Trends of prevalence of primary HIV drug resistance in Germany

Abdurrahman Sagir1, Mark Oette1,*, Rolf Kaiser2, Martin Däumer2, Gerd Fätkenheuer3, Jürgen Kurt Rockstroh4, Heribert Knechten5, Günther Schmutz6, Martin Hower7, Jetske Emmelkamp1, Herbert Pfister2, Dieter Häussinger on behalf of the RESINA Study Team1

1 Clinic for Gastroenterology, Hepatology, and Infectious Diseases, University Clinic Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany 2 Institute of Virology, University of Köln, Fürst-Pückler-Str. 56, 50935 Köln, Germany 3 Clinic I for Internal Medicine, University of Köln, Kerpenerstr. 62, 50937 Köln, Germany 4 Clinic for Internal Medicine, University of Bonn, Sigmund-Freund-Str. 25, 53127 Bonn, Germany 5 Private Practice, Blondelstr. 9, 52062 Aachen, Germany 6 Private Practice, Grafenberger Allee 128, 40237 Düsseldorf, Germany 7 Klinikum Dortmund Nord, Münsterstr. 240, 44145 Dormund, Germany

Received 16 February 2007; returned 19 June 2007; accepted 3 July 2007

* Corresponding author. Tel: +49-211/81-18942; Fax: +49-211/81-16294; E-mail: oettem{at}med.uni-duesseldorf.de

Background: Primary HIV drug resistance (PDR) is associated with poor treatment outcome of first-line highly active antiretroviral therapy (HAART). The aim of the study was to observe the trend of prevalence of PDR between 2001 and 2005.

Methods: In a prospective multicentre study in the state of Nordrhein-Westfalen, Germany, 831 treatment-naive chronically HIV-infected patients underwent genotypic resistance testing.

Results: Six hundred and forty (77%) of them were male. Two-thirds of the patients (558, 67%) were infected with HIV subtype B. PDR was found in 75 of 831 [9%; 95% confidence interval (CI) 7.1–10.9] cases entering the study between January 2001 and December 2005. An increasing trend of PDR was found from 2001 (4.8%; CI 2.1–9.4) to 2005 (9.0%; CI 5.4–12.6; P = 0.08). A significant tendency to higher PDR was observed for ethnicity other than Caucasian (P = 0.04), HIV subtypes other than B (P = 0.02) and transmission routes other than homosexual (P = 0.03).

Conclusions: A non-significant increase in prevalence of PDR was observed from 2001 to 2005. A significant trend to higher PDR rate was detected in non-Caucasian patients, patients infected with non-B subtypes, and in patients with risk factors for acquisition of HIV other than homosexual transmission. Based on the fact that there is a trend to higher PDR rate, resistance testing in untreated HIV-infected patients starting HAART becomes more important in clinical routine. The identification of patient subgroups with a remarkable risk of PDR makes continuous monitoring of PDR mandatory.

Keywords: epidemiology , HAART , RESINA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.